In Vitro and In Vivo Studies of the Biological Activity of Novel Arylimidamides against Trypanosoma cruzi | Zendy

J. S. De Araújo | Zendy; Francisca Hildemagna Guedes da Silva | Zendy; D. G. J. Batista | Zendy; P. B. Da Silva | Zendy; M. B. Meuser | Zendy; Cláudia Alessandra Fortes Aiub | Zendy; M. F. V. da Silva | Zendy; Carlos Fernando Araújo-Lima | Zendy; M. Banerjee | Zendy; Abdelbasset A. Farahat | Zendy; Chad E. Stephens | Zendy; Arvind Kumar | Zendy; David W. Boykin | Zendy; M. N. C. Soeiro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro and In Vivo Studies of the Biological Activity of Novel Arylimidamides against Trypanosoma cruzi

Author(s) -

J. S. De Araújo,

Francisca Hildemagna Guedes da Silva,

D. G. J. Batista,

P. B. Da Silva,

M. B. Meuser,

Cláudia Alessandra Fortes Aiub,

M. F. V. da Silva,

Carlos Fernando Araújo-Lima,

M. Banerjee,

Abdelbasset A. Farahat,

Chad E. Stephens,

Arvind Kumar,

David W. Boykin,

M. N. C. Soeiro

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01403-13

Subject(s) - trypanosoma cruzi , in vivo , in vitro , parasitemia , biology , chagas disease , chemistry , biochemistry , virology , parasite hosting , immunology , plasmodium falciparum , genetics , world wide web , computer science , malaria

Fifteen novel arylimidamides (AIAs) (6 bis-amidino and 9 mono-amidino analogues) were assayed against Trypanosoma cruzi in vitro and in vivo. All the bis-AIAs were more effective than the mono-AIAs, and two analogues, DB1967 and DB1989, were further evaluated in vivo. Although both of them reduced parasitemia, protection against mortality was not achieved. Our results show that the number of amidino-terminal units affects the efficacy of arylimidamides against T. cruzi.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research